NIASPAN 1000 MG EXTENDED RELEASE FILM COATED TABLETS

Nazione: Israele

Lingua: inglese

Fonte: Ministry of Health

Principio attivo:

NIACIN 1000 MG

Commercializzato da:

ABBOTT MEDICAL LABORATORIES LTD

Codice ATC:

C04AC01

Forma farmaceutica:

FILM COATED TABLETS - EXTENDED RELEASE

Via di somministrazione:

PER OS

Prodotto da:

ABBOTT LABORATORIES , USA

Gruppo terapeutico:

NICOTINIC ACID

Indicazioni terapeutiche:

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. 2.NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. 3.In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. 4.In patients with a history of coronary artery disease (CAD) and hyperlipidemia, n

Data dell'autorizzazione:

2012-08-01